SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. is facing intense scrutiny and volatility as the market reacts to the President's shifting rhetoric regarding a potential military pause in Iran. Community sentiment is deeply polarized, with critics pointing to portfolio losses and questioning the company's financial fundamentals, while supporters remain vocal about their backing of the administration's aggressive policy maneuvers.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing a significant sell-off driven by unfavorable court rulings in addiction-related lawsuits, which has triggered fears of widespread litigation and regulatory headwinds. While the company's fundamentals remain a focal point for many traders, the community is currently locked in a heated debate over whether this price action represents a temporary overreaction and buying opportunity or a deeper structural shift for the stock.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing high volatility and heavy trading volume as investors debate the impact of new AI-driven tools on its long-term moat, while the company explores a potential sale of its China business to streamline operations and bolster its balance sheet. The community remains deeply divided, with bulls pointing to the growth potential of the Vector ad platform and future AI product reveals, while others express frustration over the stock's persistent decline and the competitive pressure from emerging AI-integrated workflows.

Pelican Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2024 and is headquartered in New York, NY.

Greenland Energy Co.

Greenland Energy is trending following the completion of its business combination and the appointment of former TD Ameritrade CEO Joe Moglia as an Executive Advisor. Community members are actively speculating on the stock's potential, fueled by reports of significant oil reserves in Greenland and high-profile partnerships, leading to heavy discussion regarding the company's long-term strategic value.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo Finance is trending as the community rallies around its high-profile partnership with Franklin Templeton to bring tokenized ETFs onto the blockchain. Investors are actively discussing the project's potential to bridge traditional finance with decentralized markets, fueling widespread optimism about its long-term growth and utility.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending following strong momentum in Rezdiffra prescriptions and ongoing M&A speculation, with investors closely watching the company's ability to maintain its market-leading position in the MASH space. The community is actively debating the stock's valuation as a potential buyout candidate versus the long-term growth potential of its expanding pipeline and combination therapy strategy.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is currently trending as investors debate the sustainability of its high-yield option income strategy against ongoing NAV erosion. While some in the community highlight its role as a cashflow engine in a diversified portfolio, critics continue to emphasize concerns regarding reverse splits and long-term capital preservation.

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp

GeneDx is experiencing significant volatility and intense community debate following a sharp price decline despite reporting strong revenue growth and raised guidance. Investors are actively discussing whether the sell-off presents a long-term accumulation opportunity or a signal of deeper structural concerns regarding company financials and insider activity.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

The ARK Innovation ETF is seeing heightened volatility as community discourse centers on Cathie Wood's aggressive rebalancing, including recent divestments from tech giants like Meta and Tesla. Investors are actively debating whether these tactical shifts signal a pivot to better risk management or a lack of conviction, while others view the current price compression at key technical support levels as a potential entry point for long-term growth exposure.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing significant investor interest as the community focuses on its aggressive commercial expansion and the upcoming CVS formulary shift, which is expected to catalyze Vevye's growth. Enthusiastic shareholders are actively tracking sales force hiring and product launch timelines, with many viewing the stock as a prime opportunity for long-term growth as the company shifts toward a more mature, cash-generating phase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Moore Capital Management LP Acquires Shares of 55,000 Bio-Rad Laboratories, Inc. $BIO

Moore Capital Management LP bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to the company in its most recent filing with the...

Gotham Asset Management LLC Acquires 36,763 Shares of Bio-Rad Laboratories, Inc. $BIO

Gotham Asset Management LLC boosted its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 41.8% during the 3rd quarter, according to its most recent disclosure with the Securities...

Hound Partners LLC Has $29.15 Million Stake in Bio-Rad Laboratories, Inc. $BIO

Hound Partners LLC decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 42.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Given Consensus Rating of "Hold" by Brokerages

Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) has been given a consensus rating of "Hold" by the six research firms that are covering the stock, Marketbeat Ratings reports. One research...

Mangrove Partners IM LLC Invests $35.57 Million in Bio-Rad Laboratories, Inc. $BIO

Mangrove Partners IM LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to its most recent 13F filing with the Securities...

Perbak Capital Partners LLP Purchases 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO

Perbak Capital Partners LLP grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 171.7% in the third quarter, according to the company in its most recent 13F filing...

Portolan Capital Management LLC Has $13.02 Million Stock Position in Bio-Rad Laboratories, Inc. $BIO

Portolan Capital Management LLC reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 26.0% during the 3rd quarter, according to the company in its most recent disclosure...

10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC

Magnetar Financial LLC acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC...

Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 67.1% during the 3rd quarter, according to the company in its most recent filing with the...

Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO

Capital Research Global Investors bought a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the third quarter, according to the company in its most recent filing...

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

BIO
Bio-Rad Laboratories Inc. - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BIO News

BIOBio-Rad Laboratories Inc. - Ordinary Shares - Class A